Immunome CFO exercises options, sells 65K shares
Immunome Inc. Chief Financial Officer Max Rosett exercised stock options to acquire 71,561 shares of common stock on April 2, 2026, at exercise prices of $1.05 and $1.35 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Immunome Inc. Chief Financial Officer Max Rosett exercised stock options to acquire 71,561 shares of common stock on April 2, 2026, at exercise prices of $1.05 and $1.35 per share. These options were fully vested and had original expiration dates in 2032 and 2033.
On the same day, Rosett sold a total of 65,000 Immunome shares in open-market transactions at weighted average prices of $21.91 and $22.48 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 54,037 shares of Immunome common stock.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
6 txns
Insider
Rosett Max
Role
Chief Financial Officer
Sold
65,000 shs ($1.42M)
Approx. gross sale proceeds
$1.42M
Approx. exercise cost
$87K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 31,848 | $0.00 | $0.00 |
| Exercise | Stock option (right to buy) | 39,713 | $0.00 | $0.00 |
| Exercise | Common Stock | 31,848 | $1.05 | $33K |
| Exercise | Common Stock | 39,713 | $1.35 | $54K |
| Sale | Common Stock | 63,656 | $21.91 | $1.39M |
| Sale | Common Stock | 1,344 | $22.48 | $30K |
Holdings After Transaction:
Stock option (right to buy) — 60,000 contracts (Direct);
Common Stock — 54,037 shares (Direct)
Footnotes (4)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
- F2. The weighted average purchase price for the transaction report was $21.91, and the range of prices were between $21.44 and $22.44, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- F3. The weighted average purchase price for the transaction report was $22.48, and the range of prices were between $22.45 and $22.56, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- F4. The option is fully vested.
Key Figures
Options exercised: 71,561 shares
Shares sold: 65,000 shares
Exercise prices: $1.05 and $1.35 per share
+3 more
6 metrics
Options exercised
71,561 shares
Total underlying common shares acquired via option exercises on April 2, 2026
Shares sold
65,000 shares
Total Immunome common shares sold in open-market transactions on April 2, 2026
Exercise prices
$1.05 and $1.35 per share
Strike prices for the exercised stock options
Sale prices (weighted avg.)
$21.91 and $22.48 per share
Weighted average prices for the two reported sale blocks
Post-transaction holdings
54,037 shares
Immunome common shares directly owned by CFO after transactions
Rule 10b5-1 plan adoption date
December 26, 2025
Date CFO adopted the trading plan used for these sales
Key Terms
Rule 10b5-1 trading plan, Stock option (right to buy), weighted average purchase price, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
weighted average purchase price financial
"The weighted average purchase price for the transaction report was $21.91"
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
fully vested financial
"The option is fully vested."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Immunome (IMNM) CFO Max Rosett do in this Form 4?
Immunome CFO Max Rosett exercised stock options for 71,561 shares, then sold 65,000 shares in open-market trades. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan and left him holding 54,037 Immunome common shares directly.
What option exercises did the Immunome (IMNM) CFO report?
Rosett exercised two stock option grants covering 31,848 and 39,713 shares of Immunome common stock. The options had exercise prices of $1.05 and $1.35 per share, respectively, and were fully vested at the time of exercise according to the disclosed footnote.
Were the Immunome (IMNM) CFO’s stock sales pre-planned?
Yes. The filing states that the sales were made under a Rule 10b5-1 trading plan adopted by Max Rosett on December 26, 2025. Such plans allow insiders to schedule trades in advance, helping separate trading decisions from day-to-day company developments.
What price ranges applied to the Immunome (IMNM) CFO’s stock sales?
For the 21.91 weighted average sale, trades occurred between $21.44 and $22.44 per share. For the 22.48 weighted average sale, trades occurred between $22.45 and $22.56. The filing notes that detailed breakdowns are available upon request to the company or SEC staff.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates